254 results on '"Mehra, Ranee"'
Search Results
2. Characterization of enhancer of zeste homolog 2 (EZH2) expression, activity, and association with the tumor immune microenvironment in olfactory neuroblastoma (ONB).
3. A phase II trial of reirradiation combined with pembrolizumab in patients with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck (HNSCC).
4. Differential gene expression and methylation of upper aerodigestive tract and lung squamous cell carcinoma between European ancestry (EA) and African ancestry (AA) patients.
5. Radiomic biomarkers of locoregional recurrence: prognostic insights from oral cavity squamous cell carcinoma preoperative CT scans
6. The role of surgery and deescalation for HPV‐related oropharyngeal cancer
7. Clinical and genomic characterization of chemoradiation-resistant HPV-positive oropharyngeal squamous cell carcinoma
8. Disease and Toxicity Outcomes for a Modern Cohort of Patients with Squamous Cell Carcinoma of Cutaneous Origin Involving the Parotid Gland: Comparison of Volumetric Modulated Arc Therapy and Pencil Beam Scanning Proton Therapy
9. Radiomic Biomarkers of Locoregional Recurrence: Prognostic Insights from Oral Cavity Squamous Cell Carcinoma preoperative CT scans
10. Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma
11. Identification of CT-based non-invasive radiomic biomarkers for overall survival prediction in oral cavity squamous cell carcinoma
12. Immunotherapy in Lung Cancer: From a Minor God to the Olympus
13. Identification of CT-based non-invasive Radiographic Biomarkers for Overall Survival Stratification in Oral Cavity Squamous Cell Carcinoma
14. Tracking clonal evolution of EGFR-mutated non-small cell lung cancer through liquid biopsy: Management of C797S acquired mutation
15. Abstract CT240: On-going phase 1A clinical trial for AG01 an first-in-class anti-progranulin (GP88) monoclonal antibody in patients with advanced malignancies
16. Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
17. Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
18. Supplementary figure 4: PFS and OS by ajcc8 from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
19. Supplementary Figure 1: B cell gating from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
20. Supplementary figure 3: Cytokines and Chemokines from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
21. Supplementary figure 3: Cytokines and Chemokines from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
22. Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
23. Supplementary Figure 2: T cell gating from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
24. Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
25. Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
26. Supplementary Figure 2: T cell gating from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
27. Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
28. Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
29. Supplementary figure 4: PFS and OS by ajcc8 from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
30. Supplementary Figure 1: B cell gating from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
31. Data from Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation
32. Supplementary Figure S1 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
33. Supplementary Figure S3 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
34. Supplementary Figure S4 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
35. Data from Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation
36. Supplemental Tables and Figure Legends from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
37. Supplementary Table S1 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
38. Supplementary Table S1 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
39. Supplementary Figure S3 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
40. Supplemental Tables and Figure Legends from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
41. Supplementary Figure Legends 1-10, Table 2 from Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation
42. Supplementary Figure S2 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
43. Data from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
44. Supplementary Figure S5 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
45. Supplementary Table 1 from Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation
46. Supplementary Figures 1-10 from Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation
47. Data from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
48. Supplementary Figure Legends 1-10, Table 2 from Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation
49. Supplementary Figures 1-10 from Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation
50. Supplementary Figure S1 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.